Hiromi Wettersten

TitlePostdoctoral Scholar
InstitutionUniversity of California San Diego
Address9500 Gilman Drive #0695
La Jolla CA 92093
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Sun Q, Lesperance J, Wettersten H, Luterstein E, DeRose YS, Welm A, Cheresh DA, Desgrosellier JS. Proapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis. J Clin Invest. 2018 Jan 02; 128(1):531-544. PMID: 29227280.
      View in: PubMed
    2. Seguin L, Camargo MF, Wettersten HI, Kato S, Desgrosellier JS, von Schalscha T, Elliott KC, Cosset E, Lesperance J, Weis SM, Cheresh DA. Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers. Cancer Discov. 2017 12; 7(12):1464-1479. PMID: 28893801.
      View in: PubMed
    3. Wettersten HI, Aboud OA, Lara PN, Weiss RH. Metabolic reprogramming in clear cell renal cell carcinoma. Nat Rev Nephrol. 2017 07; 13(7):410-419. PMID: 28480903.
      View in: PubMed
    4. Trott JF, Kim J, Abu Aboud O, Wettersten H, Stewart B, Berryhill G, Uzal F, Hovey RC, Chen CH, Anderson K, Graef A, Sarver AL, Modiano JF, Weiss RH. Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer. Oncotarget. 2016 10 11; 7(41):66540-66557. PMID: 27572319.
      View in: PubMed
    5. Wettersten HI, Hakimi AA, Morin D, Bianchi C, Johnstone ME, Donohoe DR, Trott JF, Aboud OA, Stirdivant S, Neri B, Wolfert R, Stewart B, Perego R, Hsieh JJ, Weiss RH. Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis. Cancer Res. 2015 Jun 15; 75(12):2541-52. PMID: 25952651; PMCID: PMC4470795.
    6. Wettersten HI, Landesman Y, Friedlander S, Shacham S, Kauffman M, Weiss RH. Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth. PLoS One. 2014; 9(12):e113867. PMID: 25461627; PMCID: PMC4252068.
    7. Wecksler AT, Hwang SH, Liu JY, Wettersten HI, Morisseau C, Wu J, Weiss RH, Hammock BD. Biological evaluation of a novel sorafenib analogue, t-CUPM. Cancer Chemother Pharmacol. 2015 Jan; 75(1):161-71. PMID: 25413440; PMCID: PMC4400119.
    8. Tan M, Wettersten HI, Chu K, Huso DL, Watnick T, Friedlander S, Landesman Y, Weiss RH. Novel inhibitors of nuclear transport cause cell cycle arrest and decrease cyst growth in ADPKD associated with decreased CDK4 levels. Am J Physiol Renal Physiol. 2014 Dec 01; 307(11):F1179-86. PMID: 25234309; PMCID: PMC4254973.
    9. Zhang G, Panigrahy D, Hwang SH, Yang J, Mahakian LM, Wettersten HI, Liu JY, Wang Y, Ingham ES, Tam S, Kieran MW, Weiss RH, Ferrara KW, Hammock BD. Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis. Proc Natl Acad Sci U S A. 2014 Jul 29; 111(30):11127-32. PMID: 25024195; PMCID: PMC4121808.
    10. Gupta R, Dong Y, Solomon PD, Wettersten HI, Cheng CJ, Min JN, Henson J, Dogra SK, Hwang SH, Hammock BD, Zhu LJ, Reddel RR, Saltzman WM, Weiss RH, Chang S, Green MR, Wajapeyee N. Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A. Proc Natl Acad Sci U S A. 2014 Jul 29; 111(30):E3062-71. PMID: 25024194; PMCID: PMC4121806.
    11. Wecksler AT, Hwang SH, Wettersten HI, Gilda JE, Patton A, Leon LJ, Carraway KL, Gomes AV, Baar K, Weiss RH, Hammock BD. Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB. Anticancer Drugs. 2014 Apr; 25(4):433-46. PMID: 24525589; PMCID: PMC3947856.
    12. Kim K, Mall C, Taylor SL, Hitchcock S, Zhang C, Wettersten HI, Jones AD, Chapman A, Weiss RH. Mealtime, temporal, and daily variability of the human urinary and plasma metabolomes in a tightly controlled environment. PLoS One. 2014; 9(1):e86223. PMID: 24475090; PMCID: PMC3901684.
    13. Wettersten HI, Ganti S, Weiss RH. Metabolomic profiling of tumor-bearing mice. Methods Enzymol. 2014; 543:275-96. PMID: 24924138.
      View in: PubMed
    14. Abu Aboud O, Wettersten HI, Weiss RH. Inhibition of PPARa induces cell cycle arrest and apoptosis, and synergizes with glycolysis inhibition in kidney cancer cells. PLoS One. 2013; 8(8):e71115. PMID: 23951092; PMCID: PMC3737191.
    15. Liu R, Wettersten HI, Park SH, Weiss RH. Small-molecule inhibitors of p21 as novel therapeutics for chemotherapy-resistant kidney cancer. Future Med Chem. 2013 Jun; 5(9):991-4. PMID: 23734682; PMCID: PMC4573579.
    16. Zhang G, Panigrahy D, Mahakian LM, Yang J, Liu JY, Stephen Lee KS, Wettersten HI, Ulu A, Hu X, Tam S, Hwang SH, Ingham ES, Kieran MW, Weiss RH, Ferrara KW, Hammock BD. Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A. 2013 Apr 16; 110(16):6530-5. PMID: 23553837; PMCID: PMC3631682.
    17. Wettersten HI, Weiss RH. Potential biofluid markers and treatment targets for renal cell carcinoma. Nat Rev Urol. 2013 Jun; 10(6):336-44. PMID: 23545813.
      View in: PubMed
    18. Martin KS, Soldi C, Candee KN, Wettersten HI, Weiss RH, Shaw JT. From bead to flask: Synthesis of a complex ß-amido-amide for probe-development studies. Beilstein J Org Chem. 2013; 9:260-4. PMID: 23400429; PMCID: PMC3566855.
    19. Wettersten HI, Hee Hwang S, Li C, Shiu EY, Wecksler AT, Hammock BD, Weiss RH. A novel p21 attenuator which is structurally related to sorafenib. Cancer Biol Ther. 2013 Mar; 14(3):278-85. PMID: 23298903; PMCID: PMC3595311.
    20. Wettersten HI, Weiss RH. Applications of metabolomics for kidney disease research: from biomarkers to therapeutic targets. Organogenesis. 2013 Jan-Mar; 9(1):11-8. PMID: 23538740; PMCID: PMC3674034.